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Current protocols of anthracycline-induced cardiomyopathy in rabbits present with high premature mortality and nephrotoxicity,
thus rendering them unsuitable for studies requiring long-term functional evaluation of myocardial function (e.g., stem cell
therapy). We compared two previously described protocols to an in-house developed protocol in three groups: Group DOX2
received doxorubicin 2mg/kg/week (8 weeks); Group DAU3 received daunorubicin 3mg/kg/week (10 weeks); and Group DAU4
received daunorubicin 4mg/kg/week (6 weeks). A cohort of rabbits received saline (control). Results of blood tests, cardiac
troponin I, echocardiography, and histopathology were analysed. Whilst DOX2 and DAU3 rabbits showed high premature
mortality (50% and 33%, resp.), DAU4 rabbits showed 7.6% premature mortality. None of DOX2 rabbits developed overt dilated
cardiomyopathy; 66% of DAU3 rabbits developed overt dilated cardiomyopathy and quickly progressed to severe congestive heart
failure. Interestingly, 92% of DAU4 rabbits showed overt dilated cardiomyopathy and 67% developed congestive heart failure
exhibiting stable disease. DOX2 andDAU3 rabbits showed alterations of renal function, withDAU3 also exhibiting hepatic function
compromise. Thus, a shortened protocol of anthracycline-induced cardiomyopathy as in DAU4 group results in high incidence of
overt dilated cardiomyopathy, which insidiously progressed to congestive heart failure, associated to reduced systemic compromise
and very low premature mortality.
1. Introduction
Anthracyclines (AC) such as doxorubicin and daunorubicin
are regarded as one of the most effective chemotherapeutic
groups ever developed for the treatment of malignancies,
with a broad spectrum of action encompassing solid and
haematologic tumours [1, 2]. Unfortunately, AC-induced
cardiomyopathy (AICM) is a frequent toxic consequence of
AC. It is estimated that in the USA alone there are at least
10 million cancer survivors, with a similar number in Europe
[3, 4]. Thus, the recent success of chemotherapy in clinical
oncology means that the population affected by AICM will
likely increase substantially in the future.
Several animal models and protocols for the induction
of AICM in rodents (e.g., mice and rats) and lagomorphs
(e.g., rabbits) have been published over the past decades. Of
note, rabbit models of cardiac disease appear to have several
advantages over animalmodels of other species. For example,
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whilst being medium size animals, rabbits maintain a cellular
electrophysiology and Ca+2 transport system, much like in
the human or larger animals (e.g., dogs and pigs), which is
not the case for mice and rats [5]. One of the first long-
term animal models of AICM was established in rabbits by
administering daunorubicin and demonstrating myocardial
damage and fibrosis [6]. Subsequent studies in rabbits char-
acterized the cumulative and delayed nature of myocardial
lesions secondary to administration of doxorubicin 2mg/kg
weekly at different time points [7]. Most studies using rabbit
models of AICM have focused on the evaluation of potential
cardioprotective agents aimed at preventing AICM develop-
ment [8–13]. However, with the current trend of increased
life expectancy of cancer patients and their associated risk of
long-term cardiovascular sequelae, the preclinical assessment
of novel therapies (e.g., stem cell therapy) to treat this
condition requires the refinement of current animal models
to maximise their potential.
One of the main disadvantages of current protocols of
induction ofAICM in rabbits is the highmortality rate during
the induction period (30–70%) [10, 14–16]. This not only
increases the number of animals required but also limits
their utility in the evaluation of the beneficial effects of
novel therapies for AICM. Another disadvantage is that even
though cardiac toxicity is readily reproducible with some
protocols using daunorubicin or doxorubicin concomitant
systemic toxicity (e.g., nephrotoxicity) occurs with these
protocols of induction [10, 17–20]. This systemic toxicity is
often responsible for the premature death of the animals
even before they can develop clinically evident signs of
overt dilated cardiomyopathy (DCM) and congestive heart
failure (CHF). The availability of an experimental model
that provides animals in a stable clinical stage of heart
failure would offer a valuable tool to researchers interested
in evaluating the benefits of therapies that require long-term
follow-up of the animals.
Our goal has been to study the benefits of stem cell
therapy in AICM, but in the process we have come across the
pitfalls of current protocols of induction, thus motivating us
to develop our own in-house protocol. Since cardiac toxicity
is directly related to the cumulative dose administered to
the subject of study [21] and rabbits are very sensitive to
myocardial damage by AC [7], we hypothesised that increas-
ing the weekly dose of daunorubicin and reducing the length
of the protocol of induction could result in a rabbit model
of AICMpotentially exhibiting reduced nonspecific toxicities
and lower mortality. Of the several experimental protocols
trialled, here we report the incidence of overt DCM, CHF,
premature mortality, and associated systemic toxicities when
using an in-house developed shortened protocol (daunoru-
bicin 4mg/kg per week for up to 6 weeks) compared to other
protocols reported in the literature which are frequently used
for the evaluation of cardioprotective agents.
2. Materials and Methods
2.1. Animals. The experiments in the present study were
performed in accordance with Directive 2010/63/EU of the
European Commission and were approved by the Ethical
Research Committee of the University of Murcia, Spain.
A total of 37 New Zealand Rabbits (2 months old, 1.5–
2.0 kg weight with 1 : 1 ratio of males/females) were randomly
allocated into one of the following three groups: 6 rabbits
were injected I.V. 0.9% saline weekly for up to 10 weeks
and constituted the age matched controls (control group);
12 rabbits constituted DOX2 group receiving doxorubicin
(Tedec-Meiji Farma, Madrid, Spain) 2mg/kg in weekly intra-
venous injections for 8 weeks; 6 rabbits constituted the DAU3
groupwhichwas injectedwith daunorubicin (Daunoblastina,
Pfizer, Madrid, Spain) 3mg/kg in weekly for 10 weeks; and 13
rabbits constituted the DAU4 group (daunorubicin 4mg/kg
per week for 6 weeks). Due to inherent differences in the
induction times for each protocol, three time points were
defined for the comparisons of biochemical, haematological,
and echocardiographic analyses between study groups: the
first time point is the baseline time point, just before starting
the first administration of anthracycline in treated groups
or saline in control group; the second time point is the
intermediate time point, two weeks before the end of the
protocol; thus intermediate time points were at 8 weeks for
control group, 6 weeks for DOX2 group, 8 weeks for DAU3
group, and 4 weeks for DAU4 group; and the third time
point is the final time point, the last measurement taken upon
completion of the protocol.
2.2. Mortality. The premature death of the animals dur-
ing the period of induction of cardiomyopathy (i.e., death
before completing the corresponding experimental induction
protocol of weekly AC injections) was classified as follows:
(1) deaths due to systemic toxicity (i.e., directly related to
the administration of AC) which manifested as diarrhoea,
weight loss, and emaciation and included animals that died
or required euthanasia for this cause, (2) deaths secondary to
CHF (see below), which were confirmed either by echocar-
diogram and/or by autopsy, (3) other causes such as respi-
ratory failure during anaesthesia or animals that required
euthanasia (e.g., spontaneous spinal fracture). Kaplan-Meier
survival analysis was performed throughout the induction
period and up to two weeks after completion of the respective
induction protocol for each group.
2.3. Incidence of Overt DCM and CHF. For the analysis
of incidence of overt DCM and development of CHF in
the different groups of study, these were defined as follows.
Overt DCM is defined as unequivocal echocardiographic
signs of cardiac remodelling and/or functional impairment
objectively assessed by the presence of several of the following
findings: eccentric hypertrophy of cardiac chambers, loss of
the oval shape of the left ventricle, ventricular wall thinning,
increased left atrial-to-aortic root ratio> 1.5 (2D-mode, short
axis view), fractional shortening (FS) < 20%, left ventricular
ejection fraction (LVEF) < 40%, and presence of atrioventric-
ular valve regurgitation (assessed by colour and/or spectral
Doppler) (Figures 1(c) and 1(d)). On the other hand, CHF
was defined as echocardiographic and/or postmortem evi-
dence of pleural, pericardial, and peritoneal effusions and/or
pulmonary oedema in conjunction with echocardiographic
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Figure 1: Echocardiograms in 2D and M-mode during induction of AICM. Echocardiograms in 2D parasternal long axis view (a, c, e) and
M-mode of the left ventricle (LV) at the level of the papillary muscles (b, d, f). (a-b) Baseline, normal rabbit. (c-d) Rabbit with overt DCM.
(e-f) Rabbit with CHF showing 4-chamber dilatation, pericardial effusion (PE), and severely reduced LV contractility. RV, right ventricle; LA,
left atrium; RA, right atrium.
signs of overt DCM and/or severe cardiomegaly confirmed
by postmortem study (Figures 1(e) and 1(f)).
2.4. Administration of Drugs and Blood Sampling. Animals
were immobilised in acrylic restrainers to reduce stress
and facilitate the administration of drugs. AC were diluted
according to the weight of the animal in 8mL of 0.9% sterile
saline for I.V. injections in AC treated groups, whilst in
control group 8mL of 0.9% sterile saline without AC were
injected at each time point. After hair clipping of the ear
and careful asepsis, a 24G catheter was advanced into one
of the marginal auricular veins and fixed with micropore to
the skin. A winged needle (21 G) with prolongator was then
inserted into the catheter and AC were administered at a
rate of 0.5mL/min. Blood samples from jugular vein were
collected before first dose of AC and then every 2 weeks until
the final administration at 8 weeks (DOX2 group), 10 weeks
(DAU3 group), or 6 weeks (DAU4 group).
2.5. Biochemical and Haematological Study. Haematological
parameters in plasma samples were analysed using the Advia
120 Hematology System (Siemens, Erlangen, Germany).
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Biochemical parameters were evaluated in plasma using the
analyser AU2700 (Olympus Corporation, Tokyo, Japan).
2.6. Echocardiographic Study. A transthoracic echocardio-
graphic examination using a HD7 XE System, equipped with
a 4–12MHz transducer (Philips, Andover, Massachusetts,
USA) under light anaesthesia (ketamine (Imalgene, Merial,
Villeurbanne, France) 10mg/kg, combined with dexmedeto-
midine (Domtor, Esteve, Madrid, Spain) 200𝜇g/kg), was
performed longitudinally at baseline and every two weeks
until the end of the study. The procedure was performed
by or under direct supervision of a European board-
certified veterinary cardiologist (MJFP), in a blinded fashion,
according to the recommendations of the Echocardiography
Committee of the American College of Veterinary Internal
Medicine and theAmerican Society of Echocardiography [22,
23]. Simultaneous 1-lead electrocardiographic tracings were
recorded during the study. Total circumferential shortening
area (CSA) was obtained using the following formula: CSA =
CSAd − CSAs/CSAd × 100. Fractional shortening (FS (%))
was calculated according to the following formula: FS =
(LVDd − LVDs)/(LVDd × 100). Left ventricular systolic and
diastolic volumes (LVVd and LVVs) were calculated using the
Teichholz formula (7 × (LVD)3)/(2.4 + LVD) and LVEF (%)
was calculated according to the following formula: LVEF =
(LVVd − LVVs)/(LVVd × 100).
2.7. Cardiac Troponin I Evaluation. Cardiac troponin I (cTnI)
levels were determined in plasma samples obtained from
the jugular vein using the Immulite Kit (Siemens, Germany)
according to the manufacturer’s instructions with a detection
limit <0.049 ng/mL.
2.8. Histopathological Study. Heart tissue blocks were sec-
tioned to cover 5 different anatomical regions in ascending
order: the apex, free wall bellow the papillary muscles,
at the level of the papillary muscles, end of papillary
muscles and beginning of chordae tendineae, and at the
atrial level [7]. Tissue was fixed for 24 h in 10% formalin,
dehydrated with increasing ethanol concentrations, which
was then substituted for xylene, and finally embedded in
paraffin using the Leica TP1050 cyclic tissue processor (Leica
Biosystems GmbH, Germany) and the Tissue-Tek thermal
console (Sakura, USA). Sections of 5 𝜇m were then obtained
with a microtome RM2155 (Leica Biosystems GmbH, Ger-
many) and stained with haematoxylin-eosin and Masson’s
trichrome. Two pathologists blinded to study group per-
formed the histopathological evaluations. Myocardial lesions
were assigned a score from 1–4 by lesion grade, and the
extension of myocardial lesions was classified 1–4 as pre-
viously described [7]. A similar lesion grade scoring (1–4)
and classification of extension of lesions (1–4) system was
followed for kidney and liver tissue.
2.9. Statistical Analysis. Statistical analysis was performed
using SPSS Statistics version 19 for Windows and GraphPad
Prism 6. Data are expressed as means ± SEM. One-way
ANOVA with Tukey’s post hoc test or paired 𝑡 test/Wilcoxon
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Figure 2: Kaplan-Meier survival curves.
signed-rank test or two-way ANOVA to assess the global
effect of sex and treatment, where appropriate, was per-
formed. Survival curves were plotted using Kaplan-Meier
analysis (Log-Rank withMantel-Cox test). Values of 𝑝 ≤ 0.05
were considered statistically significant.
3. Results
3.1. Mortality. Survival analysis curves are shown in Fig-
ure 2. In the DOX2 group, 6 out of 12 animals (50%) died
prematurely (premature mortality defined as death of the
animal during the course of weekly I.V. administrations on
each group) during weeks 3–7 of the induction period (up
to 8 weeks), all secondary to systemic toxicity. In the DAU3
group, 33.3% died prematurely during the induction period
(up to 10 weeks); one of these deaths occurred secondary to
systemic toxicity at 4weeks and the other occurred secondary
to CHF at week 9. In the DAU4 group, only one animal
required euthanasia at week 5 due to spontaneous spinal
fracture resulting in a premature mortality of 7.6% during
the induction period (up to 6 weeks). No deaths occurred in
the control group. Gender of the animal did not influence
mortality in all AC treated groups since this did not differ
substantially from that of whole cohort within each group.
Thus, of the six deaths in group DOX2 during the induction
period, three corresponded to males and three to females.
Similarly, one death occurred in males and one in females in
the DAU3 group during the induction period, whilst for the
DAU4 group the premature death occurred in a male rabbit.
Cumulative mortality up to two weeks after completion of
the induction period continued to increase in all groups
(Figure 2). However, whilst one additional rabbit died in
the DOX2 group from 8 to 10 weeks, secondary to systemic
toxicity, and 4more deaths occurred in theDAU3 group from
10 to 12 weeks, 3 of these secondary to CHF, resulting in a
cumulative mortality of 58.3% and 100%, respectively, only
one more death secondary to CHF occurred in the DAU4
BioMed Research International 5
Table 1: Selected biochemical parameters.
Parameter Basal Intermediate§ Final
Cholesterol (mg/dL)
Control 41.5 ± 10.3 37.5 ± 10.2 44.7 ± 3.8
DOX2 36.10 ± 11.25 70.46 ± 16.66bc#¶ 241.04 ± 59.5bc#¶
DAU3 40.80 ± 4.34 45.66 ± 6.40 79.73 ± 8.20bc
DAU4 35.24 ± 7.71 44.38 ± 4.05 59.08 ± 7.81bc
Triglycerides (mg/dL)
Control 72.3 ± 22.9 45.3 ± 7.3 55.3 ± 7.1
DOX2 68.23 ± 17.48 184.70 ± 47.74b¶ 405.88 ± 38.80bc¶
DAU3 78.09 ± 20.39 150.31 ± 65.32b¶ 446.22 ± 102.9bc¶
DAU4 72.50 ± 22.85 85.04 ± 12.35 115.88 ± 15.72bc
Creatinine (mg/dL)
Control 0.86 ± 0.10 0.77 ± 0.11 0.83 ± 0.10
DOX2 0.93 ± 0.06 1.08 ± 0.08 1.62 ± 0.22bc
DAU3 0.79 ± 0.04 1.06 ± 0.10 2.54 ± 0.50bc∗¶
DAU4 0.98 ± 0.10 0.92 ± 0.10 0.87 ± 0.07
BUN (mg/dL)
Control 37.00 ± 4.95 38.54 ± 6.62 41.79 ± 8.50
DOX2 36.43 ± 3.45 30.50 ± 3.74 39.40 ± 8.69
DAU3 26.61 ± 2.99 30.92 ± 2.47 85.47 ± 12.34bc∗¶
DAU4 35.42 ± 4.57 28.35 ± 1.38 29.96 ± 2.50
Total Proteins (g/dL)
Control 5.39 ± 0.21 5.37 ± 0.22 5.33 ± 0.24
DOX2 5.48 ± 0.17 4.90 ± 0.37 3.92 ± 0.37bc¶
DAU3 5.31 ± 0.17 5.90 ± 0.30 4.42 ± 0.81bc
DAU4 5.55 ± 0.16 5.20 ± 0.12 4.96 ± 0.17
AST (U/L)
Control 23.02 ± 4.90 18.47 ± 4.10 20.77 ± 4.34
DOX2 27.59 ± 4.71 24.36 ± 6.86 30.42 ± 1.01
DAU3 20.96 ± 2.93 22.72 ± 5.82 270.9 ± 124.0bc∗¶
DAU4 35.94 ± 5.73 23.30 ± 3.84 28.31 ± 5.67
ALT (U/L)
Control 44.67 ± 8.16 39.97 ± 7.89 37.45 ± 7.37
DOX2 53.02 ± 5.34 36.98 ± 7.45 35.46 ± 4.30
DAU3 48.75 ± 6.47 54.56 ± 12.34 226.70 ± 97.2bc∗¶
DAU4 58.25 ± 13.44 45.03 ± 5.96 42.19 ± 6.88
§Intermediate time point values were from blood samples obtained on week 8 of the study in control group, on week 6 in DOX2 group, on week 8 in DAU3
group, and on week 4 in DAU4 group. BUN, blood urea nitrogen; AST, aspartate aminotransferase; ALT, alanine aminotransferase. Data expressed as mean ±
SEM. Statistical significance is at p < 0.05; bcompared to basal value; ccompared to control; ∗compared to DOX2; #compared to DAU3; ¶compared to DAU4.
group from 6–8 weeks, resulting in a cumulative mortality of
15.3%.
3.2. Incidence of DCM and CHF. None of the animals from
the DOX2 group developed overt DCM or CHF, which on
the contrary were greatly affected by general toxicity. In the
DAU3 group, 4 out of 6 animals (66%) developed overt DCM
and CHF, of which two were males and two were females.
In the DAU4 group, 12 out of 13 animals presented with
overt DCM (92%), whilst CHF was confirmed in 8 animals
(61%). In DAU4 group, the incidence of overt DCM and CHF
according to sex of the animal revealed that 6 out of 7 males
and 6 out of 6 females presented with overt DCM, whilst HF
was present in 4 out of 7 males and 4 out of 6 females.
3.3. Biochemical Study. Selected biochemical parameters are
shown in Table 1. No differences were observed between the
different groups at baseline. Triglycerides and cholesterol plus
triglycerides were significantly increased at the intermediate
time point in theDOX2 andDAU3 groups, respectively, com-
pared to basal values and control group, whilst in the DAU4
group no significant differences were observed. Also, there
were slight increases in other biochemical parameters such
as creatinine for DOX2 and DAU3 groups at the intermediate
time point; however, these remained within the normal range
for the species [24]. Groups DOX2 and DAU3 developed
marked changes in several biochemical parameters at the
final time point of the study. Thus, rabbits in the DOX2 and
DAU3 groups exhibited a significant increase in creatinine
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and marked combined hyperlipidaemia associated with a
concomitant reduction of total proteins. In addition, the
DAU3 group also showed significant increases in blood
urea nitrogen (BUN), aspartate aminotransferases (AST), and
alanine aminotransferases (ALT). Apart frommild combined
hyperlipidaemia, no significant changes were observed in
biochemical parameters in the DAU4 group at the final time
point (Table 1). Supplemental Table 1 in SupplementaryMate-
rial available online at http://dx.doi.org/10.1155/2015/465342
shows the subanalysis of selected biochemical parameters in
male and female animals from all groups at final time point.
Consistent with the general analysis, both male and female
rabbits in the DOX2 and DAU3 groups had comparable
increases in creatinine values, marked combined hyperlipi-
daemia, and reduction of total proteins in blood relative to
control group, suggesting that none of these alterations had
an underlying causality associated with sex of the animal.
However, even though these changes were marked enough
compared to control group, they were only significant in
DOX2 group, provided the low 𝑛 of animals in DAU3 group
at this time point (type II error). Similarly, and in linewith the
findings of the general analysis, DAU3 group also presented
marked alterations in BUN, AST, and ALT values in both
males and females, although low 𝑛 at this time point in DAU3
group leads to type II error (Supplemental Table 1). Male and
female rabbits from the DAU4 group only exhibited mild
hyperlipidaemia.
3.4. Haematological Study. In all AC treated groups, a sig-
nificant reduction in red blood cells (RBC), haemoglobin,
and haematocrit and increased red cell distribution width
(RDW) were observed at the intermediate time point relative
to basal time point and control group. However, whilst
in groups DOX2 and DAU4 these parameters returned to
normal levels at the end of the induction period, these
remained abnormal or even worsened in the DAU3 group at
the end of the induction period (Table 2). Consistent with
increased haematological toxicity with the DAU3 protocol,
white blood cell (WBC) count also was significantly affected
at the intermediate time point compared to baseline values
and those of control group, although these values returned to
nearly normal at the end of the induction period (Table 2).
3.5. Echocardiographic Study. All groups of the study had
comparable LVEF, FS, and total CSA at basal time point
(Figures 3(a)–3(c)). A repeated measures test within the
control group demonstrated no significant differences on
these parameters of ventricular function at the different time
points of the study. In the DOX2 group, a decrease in LVEF
and FS was observed at the intermediate time point (6 weeks)
and final time point (8 weeks), but this was only statistically
significant for LVEF at the intermediate time point (Figures
3(a) and 3(b)). Whilst at the intermediate time point LVEF,
FS, and total CSA remained unchanged in DAU3 and DAU4
groups compared to basal time point and control group,
all these parameters of ventricular function were markedly
and significantly reduced in rabbits from these groups at
the final time point (Figures 3(a)–3(c)). These changes were
also significantly different in DAU4 group when compared
to DOX2 at this time point (Figures 3(a)–3(c)). Subanalysis
of ventricular function in all groups at the final time point
indicated thatAC-inducedmyocardial damage affectedmales
and females in DAU3 and DAU4 groups to a similar extent.
Thus, marked alterations in LVEF, FS, and total CSA in males
and females were observed at final time point (Supplemental
Figures 1(A)–1(C)). However, whilst these changes were sig-
nificant in DAU4 group, low 𝑛 at final time point in DAU3
group resulted in type II error. On the contrary, ventricular
function remained equally unaffected in males and females
from DOX2 group (Supplemental Figures 1(A)–1(C)).
3.6. Cardiac Troponin I Evaluation. At the basal time point,
no differences in cTnI levels were observed among all groups.
Significant elevations were observed at intermediate time
points in all AC treated groups relative to basal time point
and control group (Figure 3(d)). The levels of cTnI further
increased at the final time point in all groups, although the
most marked increase was observed in the DAU4 group
to the extent of being statistically significant at this time
point compared to values for the DOX2 group (Figure 3(d)).
The cTnI levels in males and females were also analysed at
final time point in all groups (Supplemental Figure 1(D)).
In line with the findings for the general population, marked
elevations of cTnI were observed in both males and females
from all groups, whilst males and females from DAU4 group
exhibited the highest levels of cTnI elevation relative to
control (Supplemental Figure 1(D)).
3.7. Histopathological Examination. Figure 4 shows repre-
sentative photomicrographs of grades 1 and 4, within the
spectrum of AC induced lesions in the myocardium, kidney,
and liver, according to the grading scale used to determine the
score of lesions per organ [7]. The myocardial lesions from
all groups showed similar scores in grading scale as shown
in Table 3. Thus, the myocardium of most animals presented
predominantly with moderate myocytolysis associated with
atrophy and degeneration of myofibrils and replacement
fibrosis (Figures 4(b) and 4(c)). However, the extent of
myocardial lesions was different for all groups. Whilst DOX2
group animals presented mostly circumscribed lesions in
isolated myofibrils, myocardial lesions in animals from the
DAU3 group affected focal groups of myofibrils at 1 level,
and animals of the DAU4 group exhibited lesions involving
more extensive (diffuse) groups of myofibrils at 2 or more
levels (Table 3). Nonpurulent myocarditis associated with the
presence of mononuclear cell infiltration was also a frequent
observation in animals from all groups. Kidney and liver
lesions from all groups showed similar scores, as well as
similar extension of lesions (see Table 4).
4. Discussion
An animal model of AICM suitable to test novel thera-
pies aimed at ameliorating this condition not only should
reproduce the cardiomyopathic effect of AC in scheduled
intravenous injections, thus simulating clinical scenarios
[25], but also should have low mortality at the end of
BioMed Research International 7
Table 2: Haematological parameters.
Parameter Basal Intermediate§ Final
RBC (106/𝜇L)
Control 5.95 ± 0.24 5.93 ± 0.12 6.12 ± 0.20
DOX2 6.06 ± 0.20 4.76 ± 0.26bc 5.44 ± 0.74
DAU3 6.29 ± 0.27 4.87 ± 0.19bc 3.83 ± 0.87bc∗¶
DAU4 6.33 ± 0.25 4.84 ± 0.20bc 5.23 ± 0.23
Haematocrit (%)
Control 36.93 ± 1.76 36.88 ± 0.61 39.53 ± 0.90
DOX2 37.11 ± 1.75 28.42 ± 1.54bc 33.29 ± 2.67
DAU3 36.47 ± 1.10 29.56 ± 0.65 25.40 ± 3.56bc∗¶
DAU4 39.36 ± 0.98 29.16 ± 1.32b 33.94 ± 2.46
Hemoglobin (g/dL)
Control 12.52 ± 0.47 11.75 ± 0.23 12.82 ± 0.30
DOX2 12.21 ± 0.63 9.14 ± 0.32b 10.40 ± 1.23
DAU3 12.18 ± 0.24 8.68 ± 0.24b 6.83 ± 1.08bc∗¶
DAU4 13.07 ± 0.44 9.19 ± 0.40b 9.57 ± 0.59bc
MCV (𝜇m3)
Control 62.17 ± 2.12 62.35 ± 1.41 62.75 ± 1.78
DOX2 61.18 ± 1.87 59.95 ± 3.18 62.40 ± 3.27
DAU3 58.08 ± 1.52 60.88 ± 1.33 62.33 ± 5.03
DAU4 62.29 ± 1.75 60.28 ± 1.36 64.73 ± 3.15
RDW
Control 13.37 ± 0.74 13.95 ± 0.72 13.42 ± 1.14
DOX2 13.08 ± 0.38 18.44 ± 1.15bc 17.32 ± 1.34bc
DAU3 13.48 ± 0.28 20.26 ± 0.83bc¶ 20.47 ± 1.44bc∗
DAU4 12.27 ± 0.41 15.98 ± 0.76bc 19.78 ± 0.78bc
WBC (103/𝜇L)
Control 5.08 ± 1.22 4.86 ± 0.69 5.05 ± 0.82
DOX2 5.77 ± 0.99 6.52 ± 1.14 5.53 ± 0.76
DAU3 4.42 ± 0.64 2.88 ± 0.46bc∗¶ 7.41 ± 0.62bc∗
DAU4 5.43 ± 0.63 4.80 ± 0.72∗ 8.59 ± 1.92bc∗
Differential count (%)
Neutrophils
Control 15.55 ± 2.52 17.57 ± 1.91 22.78 ± 5.20
DOX2 18.20 ± 3.66 12.78 ± 2.49 25.70 ± 9.89
DAU3 14.10 ± 2.19 10.18 ± 4.35 11.10 ± 0.95
DAU4 31.16 ± 9.79 6.58 ± 1.60bc 27.44 ± 3.03
Lymphocytes
Control 68.55 ± 5.25 65.48 ± 2.97 63.50 ± 4.68
DOX2 68.38 ± 4.55 70.63 ± 5.21 55.90 ± 10.34
DAU3 73.27 ± 2.67 76.52 ± 5.47 72.20 ± 1.30
DAU4 55.86 ± 8.73 82.56 ± 2.14 57.15 ± 3.47
§Intermediate time point values were from samples obtained on week 6 in DOX2 group, on week 8 in DAU3 group, and on week 4 in DAU4 group. RBC, red
blood cells; MCV, mean corpuscular volume; RDW, red cell distribution width;WBC, white blood cells. Data expressed as mean ± SEM. Statistical significance
is at p < 0.05; bcompared to basal value; ccompared to control; ∗compared to DOX2; ¶compared to DAU4.
the induction period, thereby allowing sufficient time to
complete experiments to evaluate their efficacy in recover-
ing myocardial function and animal well-being. It also is
desirable that nonspecific toxicities, such as nephrotoxicity,
which do not occur in humans treated with AC [18], are
reduced or absent from the model to avoid the potential
confounding effect of comorbidities in the outcome of the
experiments. Such an animal model is currently unavailable.
The present study presents an experimental protocol for
AICM that generates a high percentage of animals with overt
DCM and CHF with mild manifestations of systemic toxicity
and very low mortality both premature (7.6%) and within
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Figure 3: Changes in echocardiographic parameters and cTnI values during induction of AICM. (a) Left ventricular ejection fraction (LVEF).
(b) Fractional shortening (FS). (c) Total circumferential shortening area (CSA). (d) Cardiac troponin I (cTnI) levels. Data expressed as mean
± SEM. Statistical significance is at 𝑝 < 0.05; (B), compared to basal; (C), compared to control; (∗), compared to DOX2; (#), compared to
DAU3; (¶), compared to DAU4.
Table 3: Scores for grade and extension of histopathological lesions
in the heart.
Group Lesion grade Lesion extension
DOX2 2.65 ± 0.39 1.65 ± 0.44
DAU3 2.63 ± 0.43 2.68 ± 0.47∗
DAU4 2.76 ± 0.32 3.18 ± 0.43∗#
Data expressed as mean ± SEM. Statistical significance is at p < 0.05;
∗compared to DOX2; #compared to DAU3.
two weeks of completing the induction protocol (15.3%).
Furthermore, the occurrence of CHF manifests insidiously
whilst cardiogenic death did not occur abruptly at the end
of the induction period, thus allowing time for functional
evaluation of the animal over an extended period of time.
These qualities result in an improvement over previously
published protocols of AICM in rabbits particularly in the
setting of evaluation of novel therapies for AICM (e.g., stem
Table 4: Scores for grade and extension of histopathological lesions
in kidney and liver.
Group Lesion grade Lesion extension
Kidney
DOX2 3.50 ± 0.71 3.50 ± 0.71
DAU3 2.75 ± 0.50 3.50 ± 0.58
DAU4 3.35 ± 0.57 3.17 ± 0.65
Liver
DOX2 3.00 ± 0.10 3.00 ± 0.10
DAU3 3.00 ± 0.75 3.00 ± 0.71
DAU4 2.88 ± 0.90 3.04 ± 0.75
Data expressed as mean ± SEM.
cell therapy). This refined model is in line with the principles
of the 3Rs and the guidelines of the National Centre for
the Replacement, Refinement and Reduction of Animals in
Research. Thus, lower premature mortality translates into
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Figure 4: Myocardial, renal, and hepatic lesions induced by anthracyclines. (a–c) Representative photomicrographs of myocardial damage.
(a) DOX2 group, grade 1: primary damage of the left ventricular myocardium. Highly intense eosinophilia of the cytoplasm, pyknotic
nuclei [P], and diffuse vacuolar degenerations in cardiomyocytes [∗] are present. (b) DAU3 group, grade 4: conspicuous disperse toxic
myocardial damage. Extensively vacuolated cardiomyocytes [∗] with intense eosinophilic cytoplasm are present. Necrotic cardiomyocytes
[N] phagocytized by macrophages [M] were gradually replaced by proliferated connective tissue (e.g., thick wavy collagen fibers [arrows]).
Mononuclear infiltrate [I] is present within the bundles of these fibers. (c) DAU3 group, grade 4: extensive fibrosis [arrows] in areas with
myocytolysis and necrosis of cardiomyocytes. (d–f) Representative photomicrographs of renal damage. (d) DOX2 group, grade 1: initial renal
tubular necrosis. Lesions of nephrosis with tubular degeneration [∗] are present. (e) DAU3 group, grade 4: focal severe nephropathy. Lesions
of nephrosis with tubular degeneration [∗] and extensive necrosis [N] of tubular cells are frequent. Fibrosis [arrow] andmononuclear infiltrate
[I] are present in these areas. (f) DAU3 group, grade 4: extensive fibrosis [arrows] in areas of toxic nephropathywith degenerations and tubular
necrosis. (g–i) Representative photomicrographs of hepatic damage. (g) DOX2 group, grade 1: initial damage of the liver. Some hepatocytes
show diffuse vacuoles inside cytoplasm [∗]. (h) DAU3 group, grade 4: hepatocytes revealed an extensive toxic damage. Necrotic hepatocytes
are present [N] and abundant hepatocytes show numerous and extensive vacuoles inside cytoplasm [∗]. (i) DAU3 group, grade 4: diffuse
fibrosis [arrows] in areas with necrotic hepatocytes. (a-b), (d-e), and (f-g): haematoxylin and eosin; (c), (f), and (i): Masson’s blue trichrome.
lower number of animals required to complete a study
(reduction), and reduced nonspecific toxicities translate into
reduced unnecessary suffering and improved well-being of
the rabbits throughout the study (refinement).
One of the salient findings of our study is that, in contrast
to the high attrition rate associated with the protocols of
induction used in DOX2 and DAU3 groups (Figure 2),
the DAU4 group exhibited very low premature mortality
(7.6%) during the induction period (with prematuremortality
defined as death of the animal during the course of weekly I.V.
administrations on each group). DAU4 group also exhibited
a significantly higher survival rate within two weeks after
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completion of the induction protocol (Figure 2). Mortality
associated with the induction of heart failure secondary to
AICM in animal models using rabbits is rarely reported.
Among the studies that do reportmortality using protocols of
induction similar to those employed in our DOX2 and DAU3
groups, the premature mortality is consistent with our find-
ings (30–50%) [10, 14, 19]. The significantly lower mortality
in DAU4 group compared to that of DAU3 could be in part
attributable to the fact that whilst higher weekly doses were
administered in DAU4 (3mg/kg/week in DAU3 compared
to 4mg/kg/week in DAU4), these were administered over a
shorter period of time (10 weeks in DAU3 versus 6 weeks
in DAU4). This likely minimises the period of AC exposure,
thus reducing the overall total cumulative dose at the end of
the induction period (30mg/kg in DAU3 group compared to
24mg/kg in DAU4). This resulted in comparable myocardial
damage between DAU4 group and DAU3 group, whilst it
reduced extracardiac toxicity/compromise in DAU4 (see also
relevant discussion below). Other protocols experimentally
trialled by us (e.g., 6mg/kg/week for 4-5 weeks) resulted in
mortalities above 50%, primarily due to toxicity, and were
therefore stopped for ethical reasons and deemed inadequate.
Another important finding of our study is that the
induction protocol used in the DAU4 group is less prone
to induce nonspecific toxicity such as nephrotoxicity and
hepatotoxicity compared to the induction protocols used in
the DOX2 and DAU3 groups. Thus, whilst the DAU4 group
did not exhibit changes in renal or hepatic function, animals
from the DOX2 and DAU3 groups presented changes in
renal function suggestive of nephrotic syndrome. Similarly,
the DAU3 group showed increased levels of AST and ALT,
suggesting compromised liver function in this group. Taking
into account these findings, it is likely that the high mortality
rate observed in the DOX2 and DAU3 groups is, at least
in part, explained by the increased incidence of nonspecific
toxic effects also observed in these groups (see also relevant
discussion below). The sensitivity to the nephrotoxic effects
of AC in rodents, which is not observed in humans [18],
has been extensively used as a model of nephrotic syndrome
which replicatesmost of the pathological features of focal and
segmental glomerulosclerosis seen in humans [26, 27]. The
nephrotoxicity observed in the DOX2 and DAU3 groups is
consistent with previous reports [10, 19, 28, 29]. Hepatotox-
icity induced by doxorubicin in rabbits has been described
previously in one report [20]; however, we did not find alter-
ations in biochemical markers of liver function in the DOX2
group. Interestingly, previous studies that used a protocol of
induction as in the DAU3 group in the present study did
not report alterations in liver function tests [10, 19]. The
reasons for these differences are unknown. Nevertheless, the
changes in AST and ALT at the final time point in the DAU3
group suggest marked hepatocellular damage. Whilst this
could be a consequence of direct AC-induced hepatotoxicity,
other mechanisms could be partially responsible as well (see
also relevant discussion below). Given the shorter period of
exposure in the DAU4 group and the absence of nonspecific
toxicities/compromise such as nephrotoxicity and hepatotox-
icity as suggested by elevations in biomarkers of kidney and
liver damage, it is reasonable to conclude that these toxicities
are in part related to the length of exposure to AC, as opposed
to cardiotoxicity, which is directly related to the cumulative
dose received, although other potential explanations are also
possible (see also relevant discussion below) [21].
In our study, haematological toxicity mostly affected red
blood cells and was common to all groups of this study
even though for most altered parameters this was transient
since this was observed at the intermediate time point and
recovered to normal or near normal levels at the final time
point in the DOX2 and DAU4 groups, whilst it remained
altered in the DAU3 group (Table 2). Haematological toxicity
consistent with myelosuppression (i.e., reduced number of
RBC, WBC, and platelets) has been reported previously
in patients treated with AC [30, 31] and appears to be a
common feature of many antineoplastic drugs [32]. We did
not observe alterations in platelet count in any of the groups
studied and only transient leukopenia in the DAU3 group,
which is consistent with previous studies using protocols of
induction similar to those used in the DAU3 group [10, 19].
The finding that this is also observed in the DAU4 group
suggests that this toxicity is independent of the scheduled
dosing of AC. Indeed, given the high activity of AC in
haematological malignancies, this toxicity could be related to
their therapeutic benefits [1, 2].
Evaluation of left ventricular function by echocardio-
graphy is a reliable noninvasive method for diagnosis of
AICM, which has good correlation with invasive catheter-
based functional analysis in rabbit models of AICM [10]. It
is interesting to note that in this study the echocardiographic
studies were planned and supervised by European board-
certified veterinary cardiologists with extensive clinical expe-
rience, which adds value to the results and ensures the
rigorousness of the studies. Monitoring of LVEF and FS
demonstrated progressive reduction in these parameters only
in the DAU3 and DAU4 groups. On the other hand, with
the exception of a transient decline in LVEF at the interme-
diate time point (6 weeks) in animals of the DOX2 group,
these parameters remained almost unchanged throughout
the induction period, and none of the animals from this
group developed overt DCM or CHF. This is in contrast to a
previous study by Gava et al. who used an induction protocol
as in theDOX2 group in our study, which found a progressive
decline in both LVEF and FS from as early as 6 weeks [15].
Similar to our findings, another study, using even higher
doses of doxorubicin (doxorubicin 3mg/kg per week for 10
weeks), also failed to demonstrate significant changes in left
ventricular function [19]. The reasons for these discrepancies
are unknown at present, however, since our histopathological
studies indicate that this group exhibited the lowest score of
extension of myocardial damage (see also relevant discussion
below); the cause of death in this groupwas exclusively due to
systemic toxicity, andmortality in the study of Gava et al. was
70% (causes and timing of these deaths were not reported) as
opposed to 50% in our study [15]; we suggest that this proto-
col of induction may not be suitable for exploring the poten-
tial benefits of novel therapies for HF secondary to AICM.
The incidence of overt DCM for the DAU3 and DAU4
groups was 66% and 92%, respectively, which ultimately
translated to an incidence of CHF of 66% (group DAU3) and
BioMed Research International 11
61% (group DAU4). Of note, whilst the development of overt
DCM and CHF in the DAU3 group was simultaneous in all
cases, this was usually full blown severeCHF and very quickly
(within a couple of days) resulted in the death of the animal, in
contrast to a more insidious presentation in the DAU4 group,
in which incidence of overt DCM was very high followed in
most cases within days by CHF, which persisted for several
weeks before death ensued. Other parameters of myocardial
damage were also more exacerbated in DAU4 group. Thus,
whilst an elevation of cTnI, a marker of myocardial cellular
damage, was observed in all groups, much higher levels
were detected in the DAU4 group at the final time point
(Figure 3(d)). Of note, none of the differences observed in
LVEF, FS, total CSA, or cTnI between DAU3 and DAU4
groups were statistically significant, despite a clear trend
(Figure 3). Elevation of cTnI has been documented previously
in rabbits treated with an induction protocol as in the DAU3
group in our study [33].
Histopathological examination revealed that whilst ani-
mals of all groups have a similar grade of myocardial lesions,
these were more conspicuous in the DAU4 group, since the
score of extension of lesions observed in this group was sig-
nificantly higher than that in the other groups (Table 3). The
histopathological findings of the heart, kidney, and liver in the
DOX2 andDAU3 groups are consistent with previous reports
[10, 15, 19]. Of note, despite marked elevations in surrogate
biomarkers of renal injury in DOX2 and DAU3 groups and
of liver injury in DAU3 group compared to DAU4 group
and control group at final time point, the scores of kidney
and liver lesions in grade and extension of damage amongst
the AC treated groups were similar upon histopathological
examination (Table 4). Whilst nephrotoxicity and hepatotox-
icity have been described in rabbits treated with AC, these
may not completely explain this lack of correlation between
blood biomarkers and histopathology findings and it is worth
elucubrating about other potential explanations. The rabbits
from DOX2 group were greatly affected by general toxicity
and exhibited the highest mortality (50%). Rabbits from
this cohort were often observed to be asthenic, subsequently
developed anorexia, and near the end of the protocol (or end
of their life) appeared cachectic, which likely resulted from an
increased catabolic state, leading to emaciation, a condition
often associated with multisystem organ failure, including
kidney damage. These observations could explain, at least in
part, the elevated creatinine observed in this group. On the
other hand, 66%of rabbits fromDAU3group developed overt
DCM which was quickly followed by progression to a severe
form of CHF, which resembled acute severe decompensated
CHF, with death ensuing within days. Hepatic (retrograde)
congestion could in part explain the increased elevations
of ALT and AST. Hypoperfusion secondary to poor pump
performance and neuroendocrine activation (which is more
marked in some forms of CHF such as acute decompen-
sated CHF) and associated peripheral and renal-splanchnic
vasoconstriction could contribute to increased renal damage
(even though renal damage secondary to CHF (cardiorenal
syndrome) is multifactorial) [34] and thus explain to some
extent elevated biomarkers of kidney injury (e.g., creatinine
and BUN) in the setting of AC treatment in this group.
Some long-term association studies indicate that among
childhood cancer survivors treated with AC girls appear
to have increased risk of developing long-term AICM [35,
36]. Interestingly, amongst adults, men appear to be more
sensitive than women to AICM [37]. Gender differences also
appear to play a role in rodent models of AICM and AC
nephropathy, with males and ovariectomized females being
more affected than females [38–40]. Although evidence is still
inconclusive, with recentmetaregression analyses and associ-
ation studies indicating that female sex is not a risk factor for
AICM [41, 42], most of the current available evidence points
to the conclusion that oestrogen could have a protective role
in AICM. We did not find any clear difference attributable
to gender in terms of mortality, incidence of overt DCM, or
congestive heart failure, as suggested by a similar percentage
of males and females from DAU3 and DAU4 groups being
affected in the present study. Similarly, at the final time point,
we did not find any significant differences in biomarkers of
cardiac (i.e., LVEF, FS, total CSA, and cTnI levels), renal (e.g.,
creatinine and BUN), or hepatic (i.e., AST and ALT) function
amongst males and females on each of the AC treated groups
(Supplemental Table 1 and Supplemental Figure 1). Thus, in
contrast to experimental studies in rodents, taken together,
our data do not support a link between gender differences
and AC toxic sensitivity in rabbits. Of note, beyond a clear
ACmediated toxicity, our studywas not powered to assess sex
differences to AC sensitivity in theDAU3 group, thus limiting
our conclusions in this respect.
Taken together, our results suggest that during the
induction of AICM the overall extracardiac physiology of
rabbits from DOX2 and DAU3 groups was more severely
compromised compared to that of the rabbits from DAU4
group, whilst DAU4 induced comparablemyocardial damage
to that of DAU3 group (Figure 3). We believe that the
refined induction protocol used in the DAU4 group could be
better suited for evaluation of novel therapies (e.g., stem cell
therapy) aimed at ameliorating the condition, given the high
incidence of overt DCM and the insidious and more stable
form of CHF that follows, which translates into increased
survival at the end of the induction period. As a note added
in proof, we have recently reported that, using the protocol
of induction as in DAU4 group and successful induction of
AICM, stem cell therapy with amniotic membrane-derived
mesenchymal stem cells (AM-MSC), administered percuta-
neously via intramyocardial injection, significantly improved
ventricular function at 2 and 4 weeks after transplant and
also significantly improved survival compared with control
group [43]. We also believe that the protocol used in DAU3
group is still very valuable in evaluation of novel cardiopro-
tective drugs, aimed at preventing development AICM in the
preclinical setting and serving as a model for the study of
pathophysiological aspects of AICM.
5. Conclusion
Our results indicate that, compared to other protocols of
induction of AICM (as in the DOX2 and DAU3 groups), a
protocol using daunorubicin 4mg/kg per week for 6 weeks
(as in the DAU4 group) results in a high percentage of
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animals with overt DCM (92%) and CHF (61%), with mild
manifestations of nonspecific systemic compromise, very low
premature mortality (7.6%) during the induction period,
and low cumulative mortality within the two weeks after
completion of the induction protocol, which translated into
a significantly higher survival rate at this stage, whilst devel-
opment of CHF was more insidious (compared to the DAU3
group, in which abrupt development of CHF was quickly
followed by death of the animals). We propose that this
refinement of the model of AICM in rabbits, which translates
into a more predictable cardiotoxicity, represents a useful
tool for the preclinical evaluation of novel therapies (e.g.,
drugs or stem cell therapy) for the treatment of heart failure
secondary to AICM, as well as the study of the molecular
mechanisms involved in the development of AICM. This
refinement is also in line with the guidelines of the National
Centre for the Replacement, Refinement and Reduction of
Animals in Research and the 3Rs principles, since the reduced
nonspecific toxicity and lower mortality would ultimately
translate into improved overall well-being of the animals
and reduced amount of animals required for this type of
research. However, we believe that the protocol used in
DAU3 group is still very valuable in evaluation of novel
cardioprotective drugs, aimed at preventing development
AICM in the preclinical setting, and for the study of the
pathophysiology of AICM.
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